Home > Insider Trading > Filing (0001553878-14-000031)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1178670	Alnylam Pharmaceuticals Inc.	ALNY	Pharmaceutical Preparations (2834)	770602661

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1514291	Michael Mason	C/O Alnylam Pharmaceuticals, Inc. 300 Third Street Cambridge MA 02142	Vp, Finance And Treasurer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2014-12-15	4,563	$9.14	6,100	No	4	M	Direct
Common Stock	Acquisiton	2014-12-15	7,937	$10.98	14,037	No	4	M	Direct
Common Stock	Acquisiton	2014-12-15	3,750	$7.10	17,787	No	4	M	Direct
Common Stock	Acquisiton	2014-12-15	4,375	$18.66	22,162	No	4	M	Direct
Common Stock	Disposition	2014-12-15	8,704	$95.10	13,458	No	4	S	Direct
Common Stock	Disposition	2014-12-15	4,128	$95.97	9,330	No	4	S	Direct
Common Stock	Disposition	2014-12-15	1,400	$97.12	7,930	No	4	S	Direct
Common Stock	Disposition	2014-12-15	900	$98.48	7,030	No	4	S	Direct
Common Stock	Disposition	2014-12-15	1,475	$99.73	5,555	No	4	S	Direct
Common Stock	Disposition	2014-12-15	1,835	$100.52	3,720	No	4	S	Direct
Common Stock	Disposition	2014-12-15	2,000	$101.75	1,720	No	4	S	Direct
Common Stock	Disposition	2014-12-15	900	$102.56	820	No	4	S	Direct
Common Stock	Disposition	2014-12-15	820	$103.60	0	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	M	Direct
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Performance-Based Stock Option (Right to Buy)	Acquisiton	2014-12-12	1,667	$0.00	1,667	$63.00
Common Stock	Stock Option (Right to Buy)	Disposition	2014-12-15	3,750	$0.00	3,750	$7.10
Common Stock	Stock Option (Right to Buy)	Disposition	2014-12-15	4,563	$0.00	4,563	$9.14
Common Stock	Stock Option (Right to Buy)	Disposition	2014-12-15	7,937	$0.00	7,937	$10.98
Common Stock	Stock Option (Right to Buy)	Disposition	2014-12-15	4,375	$0.00	4,375	$18.66

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
1,667	2014-12-12	2023-12-18	No	4	A	Direct
3,750		2021-11-30	No	4	M	Direct
0		2020-12-08	No	4	M	Direct
1,563		2021-02-28	No	4	M	Direct
5,625		2022-12-20	No	4	M	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	1,986	Indirect	By Managed Account

Footnotes

The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 21, 2014.
Sale prices ranged from $94.49 to $95.48.
Sale prices ranged from $95.52 to $96.48.
Sale prices ranged from $96.59 to $97.48.
Sale prices ranged from $98.09 to $98.69.
Sale prices ranged from $99.10 to $99.98.
Sale prices ranged from $100.20 to $101.15.
Sale prices ranged from $101.20 to $102.16.
Sale prices ranged from $102.29 to $102.83.
Sale prices ranged from $103.39 to $103.96.
The reporting person owns 1,986 shares of ALNY common stock under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program.
On December 18, 2013, the reporting person was granted a performance based stock option to purchase shares of ALNY Common Stock. One-third of the shares subject to the option will vest upon the achievement of each of three specific clinical development and regulatory events, as approved by the compensation committee of the Company. Effective December 12, 2014, the compensation committee of the Company determined the first performance criteria had been met and the option was vested as to one-third of the shares.
The stock option vests as to 25% of the shares on the first anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three-month period thereafter.